Invirsa, Inc

Pharmaceutical Manufacturing • Columbus, Ohio, United States • 11-20 Employees

Company overview

Headquarters	1275 Kinnear Rd, Columbus, Ohio 43212, US
Phone number	+16147151860
Website	invirsa.com
NAICS	3254
SIC	873
Keywords	Pharmaceuticals, Ophthalmology, Sulfur Mustard, Barda
Employees	11-20
Socials

Key Contacts at Invirsa, Inc

Matt Cromie

Director, Clinical Development

Jared Randall

Senior Director Of Chemistry, Manufacturing And Controls

Tim Willis

Member Board Of Directors

Invirsa, Inc Email Formats

Invirsa, Inc uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@invirsa.com), used 87.5% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@invirsa.com	87.5%
{first name}{last name}	johndoe@invirsa.com	12.5%

About Invirsa, Inc

Invirsa is developing a small molecule (INV-102) that promotes both DNA repair and the innate immune response to infection and injury. These actions lead to enhanced wound healing associated with reductions in inflammation and viral replication. INV-102 has demonstrated unprecedented efficacy in animal models of ocular sulfur mustard gas injury. Sulfur mustard is a dangerous chemical weapon, and INV-102 is the first drug to show promise in preventing its long-term effects. There is no current FDA approved therapy for this injury. In September of 2020, Invirsa received a $29.6M BARDA award ($14.4M plus $15.2M in milestones) to support the clinical development of INV-102 for the treatment of ocular sulfur mustard gas injury and other ocular injuries associated with DNA damage. The award covers development through Phase 3 clinical trials. Invirsa’s initial commercial focus for INV-102 will be infectious keratoconjunctivitis as there is no treatment for the viral form of this disease which comprises 80% of all cases. INV-102 has demonstrated clear efficacy in animal models of infectious conjunctivitis.

Invirsa, Inc revenue & valuation

Annual revenue	$3,000,000
Revenue per employee	$273,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$9,600,000
Total funding	$7,700,000